BerGenBio Future Growth
Future criteria checks 2/6
BerGenBio's earnings are forecast to decline at 25% per annum while its annual revenue is expected to grow at 79.4% per year. EPS is expected to decline by 4.5% per annum.
Key information
-25.0%
Earnings growth rate
-4.5%
EPS growth rate
| Biotechs earnings growth | 37.0% |
| Revenue growth rate | 79.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -317 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -208 | -223 | -220 | 2 |
| 12/31/2024 | 0 | -177 | -162 | -159 | 2 |
| 6/30/2024 | 1 | -155 | -176 | -176 | N/A |
| 3/31/2024 | 1 | -155 | -192 | -192 | N/A |
| 12/31/2023 | 0 | -190 | -225 | -225 | N/A |
| 9/30/2023 | 0 | -226 | -281 | -281 | N/A |
| 6/30/2023 | 0 | -258 | -282 | -282 | N/A |
| 3/31/2023 | 0 | -293 | -289 | -289 | N/A |
| 12/31/2022 | 0 | -302 | -288 | -288 | N/A |
| 9/30/2022 | 1 | -294 | -290 | -290 | N/A |
| 6/30/2022 | 1 | -304 | -294 | -294 | N/A |
| 3/31/2022 | 1 | -309 | -307 | -307 | N/A |
| 12/31/2021 | 1 | -309 | -303 | -303 | N/A |
| 9/30/2021 | 1 | -314 | -280 | -280 | N/A |
| 6/30/2021 | 1 | -311 | -280 | -280 | N/A |
| 3/31/2021 | 1 | -290 | -246 | -246 | N/A |
| 12/31/2020 | 1 | -257 | -234 | -234 | N/A |
| 9/30/2020 | 0 | -241 | -216 | -216 | N/A |
| 6/30/2020 | 0 | -218 | -187 | -187 | N/A |
| 3/31/2020 | 0 | -204 | -190 | -190 | N/A |
| 12/31/2019 | 9 | -199 | -187 | -187 | N/A |
| 9/30/2019 | 11 | -193 | -186 | -186 | N/A |
| 6/30/2019 | 11 | -186 | -189 | -189 | N/A |
| 3/31/2019 | 11 | -182 | -201 | -201 | N/A |
| 12/31/2018 | 2 | -192 | -187 | -187 | N/A |
| 9/30/2018 | N/A | -188 | -180 | -179 | N/A |
| 6/30/2018 | N/A | -186 | -178 | -178 | N/A |
| 3/31/2018 | N/A | -171 | N/A | -143 | N/A |
| 12/31/2017 | N/A | -182 | N/A | -168 | N/A |
| 9/30/2017 | N/A | -162 | N/A | -164 | N/A |
| 6/30/2017 | N/A | -142 | N/A | -140 | N/A |
| 3/31/2017 | N/A | -175 | N/A | -173 | N/A |
| 12/31/2016 | N/A | -130 | N/A | -124 | N/A |
| 9/30/2016 | N/A | -127 | N/A | -121 | N/A |
| 6/30/2016 | N/A | -128 | N/A | -119 | N/A |
| 3/31/2016 | N/A | -82 | N/A | -71 | N/A |
| 12/31/2015 | N/A | -72 | N/A | -63 | N/A |
| 9/30/2015 | N/A | -70 | N/A | -61 | N/A |
| 6/30/2015 | 0 | -64 | N/A | -59 | N/A |
| 3/31/2015 | 1 | -57 | N/A | -56 | N/A |
| 12/31/2014 | 1 | -58 | N/A | -54 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGBIOO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BGBIOO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BGBIOO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BGBIOO's revenue (79.4% per year) is forecast to grow faster than the UK market (3.7% per year).
High Growth Revenue: BGBIOO's revenue (79.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BGBIOO's Return on Equity is forecast to be high in 3 years time